alexa Industrial implementation of in vitro production of monoclonal antibodies.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): Dewar V, Voet P, Denamur F, Smal J

Abstract Share this page

Abstract Monoclonal antibodies are widely used at GlaxoSmithKline Biologicals (GSK Bio) for the quantification and characterization of antigens and for the release of vaccine lots. In 1998, GSK Bio decided to change the production of monoclonal antibodies (MAbs) designed for immunological tools from in vivo to in vitro technology. In 2004, all MAbs used at GSK Bio were produced in vitro. These MAbs cover more than 100 different targets with a variety of 1500 hybridomas, and approximately 60 to 90 MAbs are produced every year. This article describes the development process, including a description of the different systems tested based on double membrane or hollow fiber technology. The productivity, assets, and drawbacks of the different technologies are presented, and evaluation strategies for the choice of in vitro systems are discussed. Binding kinetics displayed by MAbs produced in vitro and in vivo were found to be similar, and MAbs produced in vitro are suitable tools for various immunological applications.
This article was published in ILAR J and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords